Widely known by its eponym Graves ' disease, diffu se hyperplasia of the thyroid gland is an autoimmune condition in which exce ss thyroid hormone production is unch ecked by the normal feedback loop between the thyroid and the pituitary gland. The immune-system abnormality is mediat ed by antibodies to the thyrotropin rece ptor found on foll icular epithelial cells. When the most specific antibody, known as thyroid-stimulating immunoglobulin (TSI), is bound to the thy rotropin receptor, the TSI mimic s the action of pituitary thyrotropin and stimulates the folli cular epithelium to produce hormone. The clin ical effect of this autoimmune process is ( I) thyro toxic osis accompanied by diffuse thyroid enlargement and an infiltrative ophthalm opathy and (2) a spectrum of the sys temic effects of excessive thyroid horm one produ ction .
Graves' disease is the most comm on cause ofspontaneous hyperth yroidism , represent ing up to 80% of all cases in the United States. Patients usually present in the third and fourth decad es of life . Gr aves' disease is much more common in wom en than men (10 : I). The wide spectrum of symptoms includes weight loss, heat intolerance, fatig ue, weakness, palpitations, dyspnea on exertion, stridor secondary to trache al compress ion, hoar sene ss, che st pain , dy spha gia, oligom enorrhea, hair loss or a change in hair texture, a gritty sensa tion in the eyes, propt osis, conj unctivitis, memory loss, poor attention span, em otional lability, muscle wea kness, and irritabilit y or agitation. In additio n to hair loss and a wide-eyed stare or proptotic appearance, physical findin gs may include localized myxedema (particularly pretibial), irritative keratoconjunctivitis, lid lag, diplopia, tachycardia, hyperactive refle xes , and smooth, warm , and velvety skin. The thyroid is diffusely enlarged, although nodul es may be see n in long standing or treated disease. Laboratory eva luatio n will show an eleva ted serum free thyroxine (T 4 ) or triiodothyronin e (T 3 ) level and a markedl y suppresse d thyroid-stimulatin g horm one level.
Th e appearance of the thyroid on low-power magni fication in Graves' disease is remark able for the accentuation of its normal lobular pattern (figure I). This change in appeara nce is attributable to an increase in the amount of fibrous tissue in the interlobular septa. A patchy lymphocytic infiltrate is often present. Moreover, the entire gland is affected by papillary hyperplasia, with the cell growth showing both hyperplasia and hypertrophy. The thyroid follicles are lined with columnar epithelialcells with basally located round nuclei and relatively dense chrom atin ; the cytoplasm is granular and eosinophilic (figure 2).The nuclei are not irregular. The hyperplastic follicul ar epithelium forms infoldings into the lumen of the follicle, produ cing a stellate outline. Vacuoles are noted along the apical aspect of the follicular cell s, giving the colloid a scallop ed appearance. Sometimes Grave s' disease is mistaken for papillary carcinoma or Hashimoto's thyroiditi s, but other histologic features will help make the distinction. Most cases of Graves' disease show treatment effect, specifically related to medical management or radioactive iodine. Potassium iodide causes involution, as follicular cells revert to their normal cuboidal or flattened appearance, alternating with areas that have retained some of the features of hyperplasia ( figure 3, A) . However, the failure rate with medical therapy is 40%, so most patients are forced to consider radioactive iodine or surgery. Radioactive iodine may produce a nodular gland; the nodul es are often quite cellul ar and may exhibit striking nuclear atypia ( figure 3, B ). Beta blockers are used to ameliorate symptoms before surgery.
The overall progno sis for patients with Graves' disease is excellent. However, thyroid storm is a life-threatening exacerbation of thyroto xicosis. 'Patients exhibit severe central nervous system and cardiac manifestations.Thyroid storm require s rapid treatment, usually with antithyr oid drugs for initial control.
